Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 18/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420264 | 1.00 | MAT2A (0.52) | MAT2APRMT5CYP3A4LMNAGFER | |
| SCHEMBL26485294 | 0.87 | MAT2A (0.53) | MAT2APRMT5CYP3A4CYP11B2 | |
| SCHEMBL30419406 | 0.87 | MAT2A (0.53) | MAT2APRMT5CYP3A4CYP11B2 | |
| SCHEMBL26091783 | 0.86 | MAT2A (0.41) | MAT2APRMT5CYP3A4LMNAGFER | |
| SCHEMBL30420438 | 0.86 | MAT2A (0.41) | MAT2APRMT5CYP3A4LMNAGFER | |
| SCHEMBL22103156 | 0.86 | MAT2A (0.66) | MAT2APRMT5CYP3A4LMNAGFER | |
| SCHEMBL29571509 | 0.86 | MAT2A (0.66) | MAT2APRMT5CYP3A4LMNAGFER | |
| SCHEMBL26485928 | 0.86 | MAT2A (0.51) | MAT2APRMT5CYP3A4LMNAGFER | |
| SCHEMBL30418873 | 0.86 | MAT2A (0.50) | MAT2ALMNAL3MBTL1 | |
| SCHEMBL26485128 | 0.86 | MAT2A (0.50) | MAT2ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-06-04 | — | — | US | disclosed |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2023066283-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | MAT2A, MAT2B, MAT1A | MAT2A 1/4885PRMT5 48/4885CYP3A4 4211/4885 |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | MAT2A, MAT2B, MAT1A | MAT2A 1/4885PRMT5 48/4885CYP3A4 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.